BR112020026899A2 - Melhorias em conjugados imunogênicos - Google Patents

Melhorias em conjugados imunogênicos Download PDF

Info

Publication number
BR112020026899A2
BR112020026899A2 BR112020026899-2A BR112020026899A BR112020026899A2 BR 112020026899 A2 BR112020026899 A2 BR 112020026899A2 BR 112020026899 A BR112020026899 A BR 112020026899A BR 112020026899 A2 BR112020026899 A2 BR 112020026899A2
Authority
BR
Brazil
Prior art keywords
polypeptide
conjugates
carrier polypeptide
saccharide
immunogenic
Prior art date
Application number
BR112020026899-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Jeffery FAIRMAN
Jon Heinrichs
Wei Chan
Original Assignee
Vaxcyte, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxcyte, Inc. filed Critical Vaxcyte, Inc.
Publication of BR112020026899A2 publication Critical patent/BR112020026899A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0216Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
BR112020026899-2A 2018-07-04 2019-07-01 Melhorias em conjugados imunogênicos BR112020026899A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862693981P 2018-07-04 2018-07-04
US62/693,981 2018-07-04
PCT/US2019/040131 WO2020009993A1 (en) 2018-07-04 2019-07-01 Improvements in immunogenic conjugates

Publications (1)

Publication Number Publication Date
BR112020026899A2 true BR112020026899A2 (pt) 2021-03-30

Family

ID=67439412

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020026899-2A BR112020026899A2 (pt) 2018-07-04 2019-07-01 Melhorias em conjugados imunogênicos

Country Status (16)

Country Link
EP (2) EP3817775B1 (https=)
JP (2) JP7399934B2 (https=)
KR (1) KR20210042904A (https=)
CN (1) CN112543649B (https=)
AU (2) AU2019299836B2 (https=)
BR (1) BR112020026899A2 (https=)
CA (1) CA3105361A1 (https=)
DK (1) DK3817775T3 (https=)
EA (1) EA202190168A1 (https=)
ES (1) ES2989087T3 (https=)
IL (1) IL279855B2 (https=)
MX (1) MX2020014118A (https=)
PH (1) PH12020552282A1 (https=)
SG (1) SG11202012905PA (https=)
WO (1) WO2020009993A1 (https=)
ZA (1) ZA202100761B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022035816A1 (en) * 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
EP4200268A4 (en) 2020-08-19 2024-10-16 Vaxcyte, Inc. CARRIER PROTEIN POLYSACCHARIDE CONJUGATION PROCESS
GB202108648D0 (en) * 2021-06-17 2021-08-04 Inst De Medicina Molecular Joaeo Lobo Antunes CRM197 protein carrier

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0375778B1 (en) 1987-06-19 1993-09-08 Terumo Kabushiki Kaisha Medical instrument and production thereof
ATE109008T1 (de) 1988-02-01 1994-08-15 Praxis Biolog Inc T-zellen-epitope als träger für einen konjugierten impfstoff.
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
JP2001190665A (ja) 2000-01-14 2001-07-17 Terumo Corp シリンジ
WO2001070763A1 (en) * 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2604363C (en) 2005-04-08 2015-06-16 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
NZ562719A (en) 2005-04-08 2008-12-24 Wyeth Corp Separation of contaminants from streptococcus pneumoniae polysaccharide by pH manipulation
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
NZ598367A (en) * 2005-09-01 2013-10-25 Novartis Vaccines & Diagnostic Multiple vaccination including serogroup C meningococcus
PL1973564T3 (pl) 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
WO2007116409A2 (en) * 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
PT2074221E (pt) 2006-10-10 2010-09-06 Wyeth Llc Métodos melhorados para a separação de polissacáridos tipo 3 de streptococcus pneumoniae
PT2129693T (pt) 2007-03-23 2017-02-14 Wyeth Llc Processo de purificação abreviado para a produção de polissacáridos capsulares de streptococcus pneumoniae
CN102307905B (zh) * 2008-12-10 2015-11-25 斯克利普斯研究院 利用化学反应性非天然氨基酸产生载体-肽偶联物
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
IT1398927B1 (it) * 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
JP2011212183A (ja) 2010-03-31 2011-10-27 Terumo Corp プレフィルドシリンジ
CN102807621B (zh) 2011-06-01 2016-04-13 厦门大学 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
EP2776069A1 (en) 2011-11-07 2014-09-17 Novartis AG Carrier molecule comprising a spr0096 and a spr2021 antigen
HRP20220455T1 (hr) 2012-08-31 2022-05-27 Sutro Biopharma, Inc. Modificirane aminokiseline koje sadrže azid grupu
WO2014053521A2 (en) 2012-10-02 2014-04-10 Novartis Ag Nonlinear saccharide conjugates
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
WO2014102265A1 (en) * 2012-12-27 2014-07-03 Glycovaxyn Ag Methods and compositions relating to crm197
ITMI20130142A1 (it) * 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
PL3055321T3 (pl) * 2013-10-11 2019-02-28 Sutro Biopharma, Inc. SYNTETAZY tRNA DOŁĄCZAJĄCE AMINOKWAS NIENATURALNY DLA PARA-METYLOAZYDO-L-FENYLOALANINY
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
IL312327B2 (en) 2014-01-21 2026-02-01 Pfizer Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
BR112016016580B1 (pt) 2014-01-21 2024-01-09 Pfizer Inc Processo para a preparação de um conjugado imunogênico, conjugado imunogênico, composição imunogênica, e vacina
CN120718167A (zh) 2014-01-21 2025-09-30 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
AU2015210674B2 (en) 2014-01-31 2017-08-24 Fina Biosolutions, Llc Expression and purification of CRM197 and related proteins
AR101455A1 (es) * 2014-08-05 2016-12-21 Glaxosmithkline Biologicals Sa Molécula portadora
EP4488286A3 (en) * 2016-03-31 2025-04-02 Pogona, Llc Saccharide-polypeptide conjugate compositions and methods of use thereof
BR112019006278A2 (pt) * 2016-09-30 2019-07-02 Biological E Limited composições de vacina pneumocócica multivalente que compreendem conjugados de polissacarídeo-proteína
ES3024474T3 (en) 2016-12-30 2025-06-04 Vaxcyte Inc Polypeptide-antigen conjugates with non-natural amino acids

Also Published As

Publication number Publication date
EP3817775B1 (en) 2024-09-04
CN112543649A (zh) 2021-03-23
JP7399934B2 (ja) 2023-12-18
KR20210042904A (ko) 2021-04-20
EP4483896A3 (en) 2025-04-02
IL279855A (en) 2021-03-01
JP2021530468A (ja) 2021-11-11
CN112543649B (zh) 2026-03-31
WO2020009993A1 (en) 2020-01-09
CA3105361A1 (en) 2020-01-09
EP4483896A2 (en) 2025-01-01
ES2989087T3 (es) 2024-11-25
SG11202012905PA (en) 2021-01-28
ZA202100761B (en) 2025-05-28
IL279855B1 (en) 2025-09-01
IL279855B2 (en) 2026-01-01
MX2020014118A (es) 2021-06-18
DK3817775T3 (da) 2024-09-16
AU2019299836B2 (en) 2025-08-21
PH12020552282A1 (en) 2021-06-28
EP3817775A1 (en) 2021-05-12
JP2024037805A (ja) 2024-03-19
EA202190168A1 (ru) 2021-06-07
AU2025256067A1 (en) 2025-11-13
AU2019299836A1 (en) 2021-02-25
JP7796716B2 (ja) 2026-01-09

Similar Documents

Publication Publication Date Title
ES2658851T3 (es) Vacunas de matriz de proteína y métodos de preparación y administración de tales vacunas
JP2022105155A (ja) 多糖類-タンパク質コンジュゲートを含む多価肺炎球菌ワクチン組成物
JP5612305B2 (ja) 免疫原性組成物を安定化させ、沈殿を阻害する新規製剤
CN103209708B (zh) 免疫原性组合物
JP7796716B2 (ja) 免疫原性複合体の改良
RU2634405C2 (ru) Иммуногенная композиция
IE58977B1 (en) Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such plysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
JP2009535353A5 (https=)
JP2013504588A (ja) 免疫原性の高いタンパク質マトリックスワクチン
BR112012009014B1 (pt) Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
HK40121270A (en) Improvements in immunogenic conjugates
JP2026071217A (ja) 免疫原性複合体の改良
EA048282B1 (ru) Усовершенствования в иммуногенных конъюгатах
HK40050310B (en) Improvements in immunogenic conjugates
HK40050310A (en) Improvements in immunogenic conjugates
HK40023130B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: VAXCYTE, INC. (US)